- Researchers made a new inhaled treatment.
- The treatment goes into the lungs.
- It aims to treat tuberculosis in the lung.
- The medicine is inside tiny particles.
- The particles go to lung immune cells.
- These cells are called macrophages.
- The particles slowly release the medicine.
- The new way may cause fewer side effects.
Difficult words
- researcher — a person who studies a subject to find factsResearchers
- inhale — to breathe air or medicine into the lungsinhaled
- tuberculosis — a disease that often affects the lungs and breathing
- particle — a very small piece or part of somethingparticles
- macrophage — a cell in the body that eats germsmacrophages
- immune — related to the body systems that fight germs
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Have you used a medicine that goes into the lungs?
- Are you worried about side effects?
- Do you like the idea of medicine in tiny particles?
Related articles
Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.
Engineered antibodies could block cytomegalovirus
A research team created changed antibodies that stop human cytomegalovirus from disabling immune responses. Lab tests show the antibodies reduce virus spread, but researchers say more testing is needed before they can be used in people.
Genes linked to chronic kidney disease
Researchers led by Alejandro Chade at the University of Missouri studied genes involved in chronic kidney disease using animal models. They found genes linked to kidney damage; silencing one gene lowered fibrosis. The team will map and test gene activity.